AstraZeneca's drug Imfinzi was approved on August 16, 2024, in the US for treating resectable non-small cell lung cancer, showing a 32% reduction in recurrence risk compared to chemotherapy alone. This approval addresses high unmet needs in early-stage lung cancer treatment.